We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Prognosis Explored for Pediatric Dilated Cardiomyopathy

By LabMedica International staff writers
Posted on 10 Oct 2022
Print article
Image: Histopathology of a biopsy from a patient with Dilated Cardiomyopathy. The myocytes have lost myofibrils and empty spaces have appeared within the cytoplasm (Photo courtesy of Professor Michael John Davies, MD, FRCPath)
Image: Histopathology of a biopsy from a patient with Dilated Cardiomyopathy. The myocytes have lost myofibrils and empty spaces have appeared within the cytoplasm (Photo courtesy of Professor Michael John Davies, MD, FRCPath)

Dilated cardiomyopathy (DCM) in children is a disease in which, due to abnormalities in the muscle, one or both ventricles in a child’s heart become enlarged and contract poorly. A variety of processes that result in myocardial damage can lead to dilated cardiomyopathy and coronary artery disease.

Genetic DCM was initially thought to be primarily caused by variants in genes encoding cytoskeletal and sarcomeric proteins. However, recent advances in sequencing and array-based technologies have increased our understanding of the genetic basis of DCM. In addition to genes encoding sarcomeric and cytoskeletal proteins, genes coding for transcription factors, ion channels, the nuclear membrane, and mitochondrial proteins are now also known to be involved in isolated DCM.

Pediatric Cardiologists at the Erasmus University Medical Center (Rotterdam, The Netherlands) and their colleagues performed a multicenter observational study in children diagnosed with dilated cardiomyopathy, from 2010 to 2017. The team originally included 144 children. Initial diagnostic categories were idiopathic dilated cardiomyopathy in 67 children (47%), myocarditis in 23 (16%), neuromuscular in seven (5%), familial in 18 (13%), inborn error of metabolism in four (3%), malformation syndrome in two (1%), and “other” in 23 (16%).

The genetic data collected were obtained retrospectively and reflect the genetic evaluation that was common practice at that time: single gene testing (e.g., Sanger sequencing of MYH7), targeted next-generation sequencing (NGS) of a gene panel (range 28-70 genes), exome sequencing (ES) with analysis of genes related to cardiomyopathy or open exome analysis. Additional genetic testing (e.g., SNP-array) was performed in a subset of patients in whom a malformation syndrome was suspected. The team defined two groups: patients with a likely pathogenic (LP) or pathogenic (P) variant (class 4 or 5) and patients without a pathogenic variant, including patients with one or more variants of unknown significance (VUS, class 3).

The investigators reported that they found a likely pathogenic or pathogenic variant in 38 children (36%), most often in MYH7 (n = 8). In one patient initially diagnosed with myocarditis, a pathogenic LMNA variant was found. During the study, 39 patients (27%) reached study endpoint (SE: all-cause death or heart transplantation). Patients with a likely pathogenic or pathogenic variant were more likely to reach SE compared with those without (hazard ratio 2.8; 95% CI 1.3–5.8), while transplant-free survival was significantly lower. Clinical characteristics at diagnosis did not differ between the two groups

The authors concluded that genetic testing is a valuable tool for predicting prognosis in children with dilated cardiomyopathy, with carriers of a likely pathogenic or pathogenic variant having a worse prognosis overall. Genetic testing should be incorporated in clinical work-up of all children with dilated cardiomyopathy regardless of presumed disease pathogenesis. The study was published on September 30, 2022 in the journal Circulation: Genomic and Precision Medicine.

Related Links:
Erasmus University Medical Center 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV Test
Anti-HIV (1/2) Rapid Test Kit
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.